Navigation Links
SGX Presents Preclinical MET Data at AACR
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. (Nasdaq: SGXP) presented abstract #4844 at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster entitled "SGX523, a potent and exquisitely selective inhibitor of the HGF receptor tyrosine kinase (MET), inhibits growth of human glioblastoma tumors in a mouse model," was presented in the afternoon poster session entitled Small Molecule Kinase Inhibitors 1 in Exhibit Hall B-F.

SGX's MET program comprises potent, selective ATP-competitive MET inhibitors, from which a number of drug-like compounds have been identified. The first development candidate, SGX523, demonstrated potent anti-tumor activity when dosed orally in various mouse models of human cancer including glioblastoma, gastric cancer and lung cancer. SGX's second development candidate, SGX126, is structurally distinct and may possess several advantages over SGX523, including the potential for a lower human dose.

"We are continuing to progress SGX126 towards IND submission, while evaluating additional follow-on compounds for our MET program," said Mike Grey, the CEO of SGX Pharmaceuticals.

About SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been imp
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
3. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
5. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
6. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
10. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... B financing, which includes both issuance of new ... approximately $2.8M in new investments in the Company.  ... raise. Funding from the Series ...
(Date:5/22/2013)... May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today ... Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of ... on May 30 at 1:30 p.m. Eastern Time.  A live ... on the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/21/2013)... , May 21, 2013  On May 9, ... ), the global business advisory firm dedicated to ... (the "Company"), announced that it has combined the ... formerly included within the Corporate Finance/Restructuring segment with ... to form a single integrated practice whose financial ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2
... TEL-AVIV, Israel and PORTLAND, Oregon, October 2 , ... Exertion Identified,Abnormalities of Cardiovascular Function and Might be Useful ... Treatment in,Clinical Practice and Trials , ... Exercise Cardiac,Output (ECO(R)) stress test protocol for chronic heart ...
... --Company to Host Conference Call-- , CALGARY, Oct. 2 ... announced that it has reached an agreement with the ... Protocol Assessment (SPA) process for the design of a ... and carboplatin in patients with platinum-refractory head and neck ...
... ... Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 -- ... series specifically for biotech and specialty pharma companies. The new series includes Situational Leadership ...
Cached Biology Technology:New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 2New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Perceptum Group Announces New Situational Leadership V Series 2
(Date:5/21/2013)... developed a new method for delivering molecules into ... cell surface. The technique could find applications in ... , Bulk electroporation a technique used to ... the cell membrane that are caused by exposing ... popular method of cell transfection. (Cell transfection is ...
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
... Rising atmospheric carbon dioxide is largely responsible for recent global ... of scientists, including two Smithsonian ecologists, have found that this ... of its negative effects on one of the planet,s most ... Proceedings of the National Academy of Sciences the ...
... has identified several common genetic variants related to a ... early online release in the journal Nature Genetics ... newly discovered, that influence the QT interval measured on ... findings could eventually help to prevent sudden cardiac death ...
... Mammalian skin requires constant maintenance, but how do skin ... In the March 23, 2009 issue of the ... colleagues reveal that skin fibroblasts use a protein called ... too quickly. Their results highlight how communications between different ...
Cached Biology News:Scientists find climate change to have paradoxical effects in coastal wetlands 2Scientists find climate change to have paradoxical effects in coastal wetlands 3Common gene variants influence risk factor for sudden cardiac death 2Common gene variants influence risk factor for sudden cardiac death 3Time (and PPAR-beta/delta) heals all wounds 2Time (and PPAR-beta/delta) heals all wounds 3
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: